A retrospective cohort study on menopause hormone therapy: menopause syndrome improvement in women aged 40 to 65 years
10.3760/cma.j.cn101441-20201104-00604
- VernacularTitle:绝经激素治疗对40~65岁女性绝经综合征改善的回顾性队列研究
- Author:
Zicheng SONG
1
;
Changbin LI
1
;
Yanwei ZHENG
1
;
Wenjun HUANG
1
;
Minfang TAO
1
Author Information
1. 上海交通大学附属第六人民医院妇产科，上海 200233
- Publication Type:Journal Article
- Keywords:
Menopause hormone therapy;
Menopause;
Age distribution;
Quality of life
- From:
Chinese Journal of Reproduction and Contraception
2022;42(3):283-286
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the impact of menopause hormone therapy (MHT) on life quality improvement in women aged 40-65 years who suffered from menopausal syndrome.Methods:A retrospective cohort study was performed to analyze the clinical data of patients aged 40-65 years attending the menopause clinic of the Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, between April 2010 and November 2019. The menopause rating scale (MRS) was implemented to evaluate the scale and severity of menopausal syndrome.Results:The total MRS scores were 9.25, 5.25, 4.67 and 4.25 before and 3, 6 and 12 months after menopausal hormone therapy, respectively. Compared with baseline, MRS score decreased significantly after menopausal hormone therapy (all P<0.001). Furthermore, After treatment, the decrease of MRS score in 50-54 years old group was significantly higher than that in 40-44 years old group ( P=0.043). Other characteristics such as marriage, income and body mass index, were not associated with the decrease of MRS score (all P>0.05). Conclusion:MHT can significantly improve menopausal syndrome in women aged 40 to 65 years, and the effect in 50-54 years old group is better than that in 40-44 years old group.
